 Intra-Cellular Therapies Incs NASDAQ: ITCI Q1 revenues reached 35.0 million, compared to 15.9 million a year ago, beating the consensus of 33.65 million. Net product revenues of Caplyta were 34.8 million, compared to 15.6 million in Q1 FY21. 